This study will evaluate the long-term safety and tolerability of tezacaftor in combination with ivacaftor (TEZ/IVA) in subjects with cystic fibrosis (CF) aged 6 years and older, homozygous or heterozygous for the F508del mutation.
Active, not recruiting
Completed the Week 24 Visit in Study 113 Part B or the Week 8 Visit in Study 115.
Eligible CFTR Mutation.
Pregnant and nursing females.
History of poor compliance with study drug and/or procedures in a previous study as deemed by the investigator.
Ongoing participation in another study with investigational drug.
Other protocol defined Inclusion/Exclusion criteria may apply.
November 1, 2022
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
For more information and to contact the study team: